ADRC Injections/STAR Trial
Allogenic Stem Cell Transplant
AM152 (Lysophosphatidic Acid 1)
Ambrisentan for Scleroderma
Bardoxolone by Reata
BEAT Clinical Trial
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support
Fludarabine/Donor Peripheral SCT
Rituximab for PAH
SAR156597 for IPF (Sanofi)
Scleroderma Lung Study II
SPIN: Patient-centered Network
Stem Cell Transplants for Scleroderma
Twins and Siblings Study
Excitement is brewing in the field of scleroderma research, as every day seems to bring new advances regarding possible causes of scleroderma as well as improved treatments.
The best way to participate in clinical trials for scleroderma is to consult a listed scleroderma expert. Admittedly, they are few and far between because this is such a rare disease, but it is well worth the extra travel and expense to get appropriate patient care.
Strategy for treatment of fibrosis in systemic sclerosis: Present and future. This review describes recent advances in the strategy for treatment of fibrosis in SSc and future perspectives. Wiley Online Library, 01/04/2016.
Flipping the switch on scleroderma. This research shows promise for the development of a new drug that can reverse the fibrosis process by flipping the main switch on all of the signaling pathways. Michigan State University, 04/03/2014.
Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? The most promising targets include inhibitors of B-cells, tyrosine kinases, 5-hydroxytryptamin receptors, interleukin-6 and Wnt signalling. PubMed, Curr Opin Pharmacol, 2013 Jun;13(3):455-62. (Also see Skin Fibrosis)
Systemic Scleroderma Symptoms. At present, there are no proven treatments or cure for any forms of scleroderma. However, there are effective therapies for many of the symptoms as well as clinical trials for specific scleroderma related symptoms. ISN. (Also see Types of Scleroderma)
Photos of Symptoms
Similar Skin Diseases
Skeletal (Bones, Muscles)
Skin and Hair
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. The difference was greater in the tocilizumab group than in the placebo group and we found some evidence of less decline in forced vital capacity. The efficacy and safety of tocilizumab should be investigated in a phase 3 trial before definitive conclusions can be made about its risks and benefits. PubMed, Lancet, 05/05/2016.
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) [focuSSced]. This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. ClinicalTrials.gov.
Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case. This report describes for the first time the efficacy of an anti interleukin-6 agent in Eosinophilic fasciitis treatment. PubMed, Joint Bone Spine, 07/07/2015.
Genentech Granted FDA Breakthrough Therapy Designation for Actemra® for Systemic Sclerosis. On June 10, 2015, Genentech announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation status to ActemraŽ (tocilizumab) for the treatment of systemic sclerosis (also known as scleroderma), a rare and potentially life-threatening disease with no FDA-approved therapy. ISN News Release, 06/10/2015.
Actemra Looks Promising in Scleroderma. Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis in a proof-of-concept study. Medpage Today, 04/29/2015.
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis. This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with systemic sclerosis. ClinicalTrials.gov.
Daval AIMSPRO as monotherapy in scleroderma yields positive results. The double-blind placebo-controlled phase II clinical study to assess the safety and tolerability of AIMSPRO as a monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma) yielded positive results. PBR Clinical Trials. 10/11/2011.
Cytori’s Managed Access Program. Cytori’s Managed Access Program in select countries across Europe, the Middle East, and Africa is intended to provide patients with hand impairment due to scleroderma early access to ECCS-50 therapy. Cytori Theraputics Inc.
Cytori Therapeutics Completes Patient Enrollment in Phase 3 STAR Trial for Scleroderma Cytori Therapeutics recently announced that its FDA-approved Phase 3 STAR clinical trial evaluating ECCS-50 has enrolled and treated its 80th patient, reaching 100 percent of its target enrollment. Scleroderma News, 05/31/2016.
Cytori’s phase III scleroderma trial achieves progress. Cytori Therapeutics, a biotechnology company, said its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 40th patient, or 50% of target enrollment. Pharmiweb.com, 03/25/2016.
Cytori Granted SME Status by European Medicines Agency The European Medicines Agency's (EMA) Micro, Small and Medium-sized Enterprise (SME) office has granted SME status to Cytori Therapeutics. Business Wire, 03/23/2016.
Cytori’s phase III scleroderma trial achieves progress. Cytori Therapeutics, a biotechnology company, said its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 20th patient, or 25% of target enrollment. Pharmiweb.com, 01/25/2016.
First Patient Treated in the U.S. STAR Trial. Cytori has successfully begun its first ever U.S. approval trial and consistent with their experience in treating scleroderma in Europe, the patient tolerated the procedure well. Cytori, 08/25/2015.
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR). The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma. ClinicalTrials.gov, 08/24/2015.
FDA Approves Cytori U.S. Pivotal Scleroderma Trial. The STAR trial will begin enrolling in 2015 and will include 80 patients, in up to 12 centers in the United States. The trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of a single administration of Cytori's lead cellular therapeutic, ECCS-50, in scleroderma patients with hand dysfunction. MarketWatch, 01/12/2015.
Cytori Therapeutics Receives Approval for Scleroderma Study in France. Per the study protocol, 13 patients will receive an injection of their own adipose-derived stem and regenerative cells (ADRCs) into the affected areas of their fingers. StreetInsider. 10/23/12.
|Overview of Stem Cells and Stem Cell Transplants
Bristol-Myers Squibb acquires Amira Pharmaceuticals. AM152, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist has completed Phase I clinical studies and is poised for Phase IIa proof-of-confidence studies for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic Sclerosis (SSc), or scleroderma. Marketizer. 09/12/2011.
Orphan Drug Status For LPA1 Antagonist AM152 For Treatment Of Idiopathic Pulmonary Fibrosis. Amira Pharmaceuticals, Inc. announced today that AM152, the company's lead LPA1 antagonist, has been granted an orphan drug designation by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. e!sciencenews. 04/22/2011.
The recruitment status of this study is unknown
because the information has not been verified recently. 10/15/12.
Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis. The hypothesis on which we are basing this study is that an endothelin receptor antagonist and disease modifying agent with antifibrotic properties will have additive influence on fibrosis, inhibit cellular and humoral hyperactivity and interfere with smooth muscle proliferation in the vessel wall. The combination of these two agents will also be the first regimen to address the heterogeneity of scleroderma manifestations including ILD, pulmonary arterial hypertension and skin manifestations. ClinicalTrials.gov. Identifier: NCT01093885.
Reata's Bardoxolone Methyl as PAH Therapy Shows Promise in Initial Phase 2 Data. In the LARIAT trial, efficacy analyses showed bardoxolone methyl increased 6MWD at doses of 2.5 to 10 mg through 16 weeks of treatment. Pulmonary Hypertension News, 10/27/2015.
Pre-Qualification Survery for BEAT Clinical Trial. The investigational oral drug in this trial is called Beraprost Sodium-314d-Modified Release (BPS-314d-MR). This study will help researchers determine if the combination of the investigational oral drug and the inhaled medicine Tyvaso® (treprostinil) is safe and effective in delaying the progression of PAH. Lung Biotechnology Inc.
Tracleer® is by Actelion Pharmaceuticals US, Inc.
Tracleer® (Bosentan) appears to be beneficial for a variety of scleroderma symptoms, such as digital ulcers, pulmonary fibrosis, pulmonary hypertension, and skin fibrosis. ISN.
Tracleer for Digital Ulcers
Tracleer for Heart Involvement in SSc
Tracleer for Pulmonary Fibrosis
Tracleer for Pulmonary Hypertension
|Tracleer for Raynaud's
Tracleer for Scleroderma Renal Crisis
Tracleer for Skin Fibrosis
Cyclophosphamide and Revimmune for Scleroderma Lung Disease. Clinical trial and research information on cyclophosphamide for pulmonary alveolitis. ISN.
|SCOT Clinical Trial
SCOT Substudy 01
Northwestern University Clinical Trials
|Scleroderma Lung Study II
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support Clinical Trial. To evaluate the efficacy (phase II) of two treatment modalities: pulse cyclophosphamide versus high dose cyclophosphamide and rATG (rabbit antithymocyte globulins) rescued with autologous peripheral blood stem cell transplant (PBSCT). Northwestern University. ClinicalTrials.gov.
Oral treprostinil diethanolamine for pulmonary arterial hypertension. Emerging data suggest that in carefully selected patients oral treprostinil may be able to replace continuously infused treprostinil. PubMed, Expert Rev Clin Pharmacol, 2015 Jan;8(1):55-60.
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (DISTOL-1). This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets (compared to placebo) on digital ulcers in patients with scleroderma. ClinicalTrials.gov. (Also see Digital Ulcers)
Fludarabine and Total-Body Irradiation Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis. This phase II trial is studying how well giving fludarabine together with total-body irradiation followed by a donor peripheral stem cell transplant works in treating patients with severe systemic sclerosis. Clinical Trials.gov.
Study Shows Treatment with Fresolimumab Able to Reduce Skin Scarring in Systemic Scleroderma patients. Fresolimumab, sponsored by Genzyme, a drug agent that targets a chemical mediator in the body called TGF-beta, is able to block scarring which could mean a major treatment advance for scarring-mediated organ dysfunction. Scleroderma News, 06/23/2015. (Also see Causes of Scleroderma: Molecular Defect and Skin Fibrosis)
Fresolimumab In Systemic Sclerosis. The purpose of this study is to determine if fresolimumab, which is sponsored by Genzyme, is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals. ClinicalTrials.gov. 07/15/2014.
IVIG Treatment in Systemic Sclerosis. The primary outcome measure is to study the effects of IVIG on the skin in patients with scleroderma. Study centers are Georgetown University and Johns Hopkins. NIH.
JB Therapeutics raises $662K to start scleroderma trial. The company plans to use the money to run a Phase 2 clinical trial in the orphan disease systemic sclerosis, a type of scleroderma that affects the skin and vital internal organs such as the lungs, heart, and kidneys. Boston Business Journal. 04/11/12.
Safety and Tolerability of MEDI-551 in Subjects with Systemic Sclerosis (SSC): Results from A Phase 1 Randomized, Placebo-Controlled Escalating Single-Dose Study. Rapid sustained B-cell depletion was observed following single IV infusion of MEDI-551. Clinical activity was suggested by decreased mRSS. Ann Rheum Dis, 2014;73:562.
Study Reveals Promising Data on Nilotinib as a Therapy for Diffuse Systemic Sclerosis. Nilotinib was generally well-tolerated by systemic sclerosis patients. In terms of efficacy, controlled trials with a larger number of patients should be conducted in order to draw definitive conclusions, although the pilot study showed a significant improvement in MRSS. Scleroderma News.
Study Reveals Promising Data on Nilotinib as a Therapy for Diffuse Systemic Sclerosis. Nilotinib was generally well-tolerated by systemic sclerosis patients, with tolerability being primarily limited by mild cardiovascular side effects. Scleroderma News, 08/24/2015.
Nilotinib (Tasigna) in the Treatment of Systemic Sclerosis. This Phase II Open Label study is currently recruiting participants. The purpose of this study is to learn how safe and tolerable a medication called Nilotinib (Tasigna) will be for patients diagnosed with Systemic Sclerosis. The secondary goal is to assess how effective Nilotinib is in treating patients with scleroderma. ClinicalTrials.gov. (Also see Scleroderma Clinical Trials: Current Studies)
OFEV (nintedanib) to Be Tested in Systemic Sclerosis Patients (SSc) with Interstitial Lung Disease (ILD). The potential use of nintedanib in conditions that commonly occur with fibrotic lung conditions, such as systemic sclerosis are being investigated. Scleroderma News, 12/22/2015. (Also see Pulmonary Fibrosis Treatments)
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis. It is the purpose of the trial to confirm the efficacy and safety of nintedanib 150 mg bid in treating patients with systemic sclerosis – interstitial lung disease, compared with placebo. ClinicalTrials.gov. 11/17/2015.
Opsumit® (Macitentan) Prescribing Information. This is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1). PAH is high blood pressure in the arteries of your lungs. Actelion Pharmaceuticals US, Inc.
Clinical Trial: Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (DUAL-2). The primary objective is to demonstrate the effect of macitentan on the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcers (DU). ClinicalTrials.gov. 12/18/12. (Also see Digital Ulcer Treatments and Digital Ulcers Research)
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease. The purpose of this first study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of pomalidomide (CC-4047) in the treatment of subjects with diffuse cutaneous systemic sclerosis with interstitial lung disease. Study ID NCT01559129. ClinicalTrials.gov. 10/15/12. (Also see Diffuse Scleroderma and Pulmonary Fibrosis Research)
Corbus Pharmaceuticals Receives FDA Approval for Open–Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis. Corbus Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted approval for a 12–month open–label extension study of the ongoing Phase 2 clinical trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Corbus Pharmaceuticals, 04/12/16.
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis. Corbus Pharmaceuticals announced today that the first subject was dosed in the Phase 2 clinical study of its investigational new drug Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Corbus Pharmaceuticals, 10/07/15.
Corbus Pharmaceuticals Initiates Phase 2 Study Patient Enrollment of Resunab for Systemic Sclerosis. Corbus Pharmaceuticals recently announced the initiation of patient enrollment for its Phase 2 trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Scleroderma News, 09/02/2015.
Investigational Scleroderma Drug Takes Novel Approach To Treating Inflammation. A new proposed treatment for scleroderma, Resunab, will soon be in Phase 2 clinical trials. Scleroderma News, 03/16/2015.
Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. These data provide further evidence of B-cell involvement in the pathogenesis of scleroderma and targeting B cells may be a promising treatment for scleroderma patients. PubMed, Clin Exp Rheumatol, 2015 Sep-Oct;33 Suppl 91(4):160-167. (Also see B Cells and T Cells)
Rituximab in diffuse cutaneous systemic sclerosis (SSc): should we be using it today? We summarize the therapeutic use of rituximab in SSc and the basic science evidence suggesting that B cells and autoantibodies are the primary drivers of fibrosis in skin and lung tissue. PubMed, Rheumatology (Oxford), 07/01/2015. (Also see Causes of Scleroderma: B Cells and T Cells)
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Rituximab (RTX) may favorably affect skin fibrosis through attenuation of PDGFR expression and activation, a finding that supports a disease-modifying role of RTX in Systemic Sclerosis (SSc). Arthritis Res Ther, 2012 Jun 14;14(3):R145. (Also see Causes of Scleroderma: B and T Cells)
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). This trial will determine if rituximab, an immunotherapy, has a marked beneficial effect on clinical disease progression, with minimal toxicity, in patients with SSc-PAH when compared to placebo. ID NCT01086540. ClinicalTrials.gov.
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF). To assess in safety and tolerability of ascending doses of SAR 156597 in adult patients with Idiopathic Pulmonary Fibrosis (IPF), administered subcutaneously once weekly over a 6-week period. Sanofi. ClinicalTrials.gov.
Fewer Mycophenolate Adverse Events in Scleroderma Lung Study. Mycophenolate mofetil can be substituted for cyclophosphamide for the immunosuppressive treatment of scleroderma-related interstitial lung disease and might even be safer. Medscape, 11/02/2015. (Also see Pulmonary Fibrosis Treatments and Immunosuppressants)
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) (SLSII). The purpose of this study is to determine whether people with symptomatic scleroderma-related interstitial lung disease experience more respiratory benefits from treatment with a 2-year course of mycophenolate mofetil or treatment with a 1-year course of oral cyclophosphamide. ClinicalTrials.gov.
The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT). The use of the cmRCT design, the development of self-guided online interventions and partnerships with patient organisations will allow SPIN to develop, rigourously test and effectively disseminate psychosocial and rehabilitation interventions for people with SSc. BMJ Open, 2013;3:e003563.
|Overview of Stem Cells and Stem Cell Transplants
Phase 3 Trial to Begin for Terguride in Diffuse Cutaneous Scleroderma. The German pharmaceutical company Medac, in August, will begin Phase 3 of a clinical trial to access the therapeutic potential of terguride, a disease–modifying drug for the treatment of diffuse cutaneous systemic sclerosis. Scleroderma News, 06/09/2016.
Still enrolling as of 10/15/12.
Families with Twins or Siblings where one has Systemic Rheumatic Disorders (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Lupus, Scleroderma, or Myositis) and one does not. The goal of study 03-E-0099 is to assess why one twin or sibling developed disease and why the other brother or sister did not.
The siblings may or may not be twins, but must be of the same gender and be within a 3-year age difference. Biological parents, or, in some cases, children, will also be included in the study.
Families may enroll at the NIH Clinical Center in Bethesda, Maryland, just 9 miles north of Washington, DC or at their local physician's office. Transportation assistance may be available and there is no charge for study-related evaluations and medical tests.
For information on the study, call the NIH patient recruiting office toll free at 1-800-411-1222 (For TTY: 1-866-411-1010). National Institutes of Health Clinical Center (NIH). 11/25/05. (Also see Scleroderma Research Registries and Causes of Scleroderma: Genetics)
Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for Phase II clinical program for Vasculan™ in patients with systemic sclerosis. Cumberland Pharmaceuticals, 04/27/2016.
Velcade® (Bortezomib) is being studied in clinical trials for scleroderma pulmonary fibrosis.
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis. This is a Phase II clinical trial at Northwestern. It is still recruiting as of March 2016. Clinicaltrials.gov.
Cancer drug may also work for scleroderma. In mouse models and human fibroblast cells, Bortezomib (brand name Velcade), which is used to treat multiple myeloma, appears to put the brakes on abnormal development of scar tissue in the lungs and skin and may also work in other organs. Northwestern University, Eurekalert, 09-22-11.
This study is currently recruiting participants.
Zibotentan Better Renal Scleroderma Outcome Study (ZEBRA) The purpose of this study is to see how effective a new endothelin blocker called Zibotentan is in treating patients who have scleroderma and have gone on to develop reduced kidney function as a complication. ClinicalTrials.gov.
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Cindy Dorio, Shelley Ensz, and Michele Maxson.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.